Pharmaceuticals, Biotech & Life Sciences Brands · Advertiser / Brand
Sanofi
Biopharmaceutical company selling medicines, vaccines and consumer health products.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Sanofi S.A.
- Entity type
- COMPANY
- Headquarters
- 46, avenue de la Grande Armée, 75017 Paris
- Company size
- >5,000
- Market cluster / sector
- Pharmaceuticals, Biotech & Life Sciences Brands
- Market role
- Advertiser / Brand
- Ticker
- SNY
- Official website
- sanofi.com
What Sanofi does
Sanofi creates value by investing in R&D, developing regulated therapies and vaccines, securing approvals, manufacturing at scale and distributing products through healthcare and retail channels. Its revenue base combines prescription product sales, vaccine sales, consumer healthcare sales and selective licensing or partnership income, with value concentration in branded and differentiated assets supported by global commercial infrastructure.
Category differentiation
Sanofi is a pharmaceutical and vaccines manufacturer, not an adtech, martech or software platform vendor. Its content properties support corporate communication and consumer health discovery rather than constituting its core revenue engine.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Sanofi S.A. is a public biopharmaceutical company headquartered in France. It discovers, develops and commercialises prescription medicines and vaccines, and it also operates a consumer healthcare division under the Opella brand. The company serves healthcare systems, providers, pharmacies, distributors, patients and consumers across multiple markets through regulated pharmaceutical and consumer health channels.
Company news briefing
Briefing updated:
Sanofi is advancing its strategic partnership with Cheplapharm for mature medicines to streamline operations and reallocate capital towards core growth drivers. Additionally, the European Union has granted expanded marketing authorisation for the MenQuadfi vaccine in infants aged six weeks and older, strengthening the company's pediatric portfolio. Furthermore, Sanofi's consumer healthcare business, Opella, is scaling AI-driven creative production to significantly increase digital asset output.
Business model & monetisation
Sanofi monetises through product sales of prescription medicines, vaccines and over-the-counter consumer healthcare products, supplemented by licensing and partnership arrangements. Commercial pricing is shaped by patent protection, regulatory frameworks, negotiated reimbursement and retail pharmacy sell-through, rather than software subscriptions or advertising.
- Prescription medicines
- Branded and reimbursed product sales
- Vaccines
- Institutional and healthcare channel product sales
- Consumer healthcare
- Retail and pharmacy OTC product sales via Opella
- Licensing and partnerships
- Licensing, collaboration and related commercial agreements
Products & capabilities
No products with linked sources are available in this view.
Unlock Full Intelligence Profile for Sanofi
Get unlimited access to corporate ownership, historical M&A transactions, verified tech stack telemetry, and live market signals in the interactive Knowledge Graph.
Verified Ownership & Corporate Hierarchy
Complete corporate hierarchy traversal, shareholder cap table history, and parent holding links sourced from regulatory filings.
360° Tech Stack & Vendor Telemetry
Technical header bidding configurations, sellers.json registry nodes, CMP disclosures, and direct programmatic supply chains.
Live Market Signals & Executive Briefings
Continuous 24/7 monitoring of material M&A deals, executive shifts, product rollouts, and hiring trends across peer entities.
Competitors & alternatives
Track competitor shifts
Receive automated telemetry on strategic moves, acquisitions, and market share shifts across Sanofi's competitive landscape.
German science group spanning life science, healthcare and electronics.
Global pharmaceutical company selling medicines and vaccines.
Pharmaceuticals, diagnostics and digital health software for healthcare.
Biopharmaceutical company developing and commercialising prescription medicines.
Diversified life sciences company spanning pharmaceuticals, consumer health and agriculture.
Side-by-side comparisons
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
6-K Financial Filing Analysis for Sanofi (2026-10-30)
financials · Recorded impact score: 4.1/5
On October 30, 2026, Sanofi furnished a Form 6-K to the SEC incorporating a press release announcing its financial results for the third quarter ended September 30, 2026. The report highlighted double-digit growth in both net sales and business earnings per share (EPS). Driven by robust operational performance across key therapeutic areas, management upgraded its full-year 2026 financial guidance. The filing confirms continued commercial momentum and underscores positive operating leverage ahead of year-end reporting.
- Sanofi reported double-digit growth in both sales and business EPS for the third quarter of 2026.
- Management officially upgraded its full-year 2026 financial guidance as reflected in Exhibit 99.1.
6-K Financial Filing Analysis for Sanofi (2026-10-26)
financials · Recorded impact score: 3/5
Sanofi filed a Form 6-K on October 26, 2026, incorporating a press release dated October 19, 2026, regarding the groundbreaking of a new state-of-the-art insulin manufacturing facility in Germany. The investment reinforces Sanofi's global production network and long-term manufacturing capacity for its diabetes care portfolio. This expansion aims to strengthen supply chain resilience, modernize biomanufacturing capabilities, and secure insulin supply across European and international markets.
- Sanofi initiated construction on a new state-of-the-art insulin manufacturing facility located in Germany.
- The underlying operational milestone was formally announced via an exhibit press release dated October 19, 2026.
Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Recorded impact score: 2/5
Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
6-K Financial Filing Analysis for Sanofi (2026-10-01)
financials · Recorded impact score: 4.1/5
On October 1, 2026, Sanofi filed a Form 6-K with the U.S. Securities and Exchange Commission announcing an expansion of its global alliance with Regeneron Pharmaceuticals. The collaboration will encompass multiple next-generation, long-acting immunology antibodies, building upon their established partnership responsible for blockbuster treatments such as Dupixent. This strategic move aligns with Sanofi's 'Play to Win' roadmap, reinforcing its specialty care pipeline and solidifying its leadership in large-market immunological therapies.
- Sanofi and Regeneron expanded their global alliance to develop and commercialize multiple next-generation, long-acting immunology antibodies as of October 1, 2026.
- The material agreement was formally reported to the SEC via Form 6-K under Exhibit 99.1.
6-K Financial Filing Analysis for Sanofi (2026-09-17)
financials · Recorded impact score: 3.4/5
On September 17, 2026, Sanofi submitted a Form 6-K filing with the U.S. Securities and Exchange Commission incorporating a press release dated September 14, 2026. The filing announces a new strategic partnership between Sanofi and Cheplapharm focused on mature medicines. This partnership reflects Sanofi's ongoing portfolio optimization strategy, allowing the company to streamline operations, monetize or efficiently manage established pharmaceutical assets, and reallocate focus and capital toward core growth drivers and innovative pipeline therapies.
- Sanofi entered into a strategic partnership with Cheplapharm focused on its mature medicines portfolio, originally announced via press release on September 14, 2026.
- The Form 6-K regulatory submission was formally executed and signed on September 17, 2026, by Alexandra Roger, Head of Legal Corporate & Finance.
Explore company relationships
Questions about Sanofi
What is Sanofi?
Sanofi is a public biopharmaceutical company that develops and sells medicines, vaccines and consumer healthcare products.
Who uses Sanofi?
Healthcare systems, hospitals, physicians, pharmacies, distributors, patients and OTC consumers use Sanofi products and information services.
How does Sanofi make money?
Sanofi makes money from prescription medicine sales, vaccine sales, OTC consumer health sales and selected licensing or partnership income.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
10 publicly documented primary sources and citations linked across the market graph.
Continue your research on Sanofi
Open additional company details, personal Watchlists and your Strategic Intelligence Agent in Polaris7. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Daily intelligent monitoring · Verified primary sources.
Unlock full intelligence profile, ownership & live market signals